CardioMotion:通过亮场动力成像识别小分子中的功能性和结构性心脏毒性负债
William Stebbeds1, Kavita Raniga1,2, David Standing1
1Screening Profiling and Mechanistic Biology, GSK, Stevenage, SG1 2NY, UK.
概括
CardioMotion是一种新的测试方法,可检测心肌细胞中药物诱导的心血管毒性. 这种高通量方法识别了影响心肌细胞击败的化合物,改善了早期药物安全性评估.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
- 药物开发 药物开发
背景情况:
- 心血管毒性导致严重的药物开发失败和市场后撤销.
- 当前的体外试验测试往往无法检测结构性心脏毒性,这在长期暴露后表现出来.
- 早期发现心血管疾病对药物安全至关重要.
研究的目的:
- 推出 CardioMotion,一种新的无标签,高通量体外试验法,用于评估药物诱导的心脏毒性.
- 评估 CardioMotion 在识别具有已知的功能和结构心脏毒性机制的化合物的有效性.
主要方法:
- CardioMotion使用高率亮场成像来记录心肌细胞自发的跳动.
- 一个基于光流的Python管道分析图像,生成参数化的波形数据.
- 该试验评估了心肌细胞跳动模式中化合物诱导的干扰.
主要成果:
- CardioMotion确定了具有已知的机制的心脏活性化合物 (72.9%的灵敏度).
- 该试验有效检测出已知的结构性心脏毒素 (86%的灵敏度).
- 卡迪奥运动方法的高特异性为82.5%.
结论:
- CardioMotion是一种敏感和特定的体外检测试验,用于检测功能性和结构性心脏毒性.
- 这种高通量方法为药物开发中的早期心血管安全评估提供了有价值的工具.
- CardioMotion可以帮助缓解因心脏毒性而导致的药物失败和戒断.
更多相关视频
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
3.2K
10:30Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: August 4, 2022
2.9K
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...